US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files

 
• By Derrick Gingery
  
FDABldg1ExteriorWithCircle_1200x675
The FDA's proposed rule is intended to ease the burden of the 2020 biologics transition process. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics